Ketogenic diet improves renal Fanconi syndrome in nephropathic cystinosis: first human proof-of-principle from an n-of-1 pediatric study

Abstract Cystinosis is a rare inherited metabolic disorder caused by pathogenic variants in the CTNS gene and characterized by progressive lysosomal cystine accumulation in virtually all organs and tissues. Clinically, the disease presents with renal Fanconi syndrome (RFS) during the first year of life and, if left untreated, progresses to end-stage kidney disease around the age of 10 years. In addition to renal involvement, cystinosis affects multiple extra-renal organs, including the eyes, thyroid gland, muscles, brain, pancreas, and gonads. Treatment with the cystine-depleting agent cysteamine delays disease progression. In two rodent models of cystinosis (mouse and rat), a ketogenic diet (KD) has recently been shown to markedly improve features of RFS and chronic kidney injury. Inspired by these findings, we initiated KD treatment in a 7-year-old boy with cystinosis and RFS. The diet was administered via a gastrostomy tube for six months. Following an initial adaptation period, the intervention was well tolerated. After three and six months of treatment, we observed substantial improvements in proximal tubular reabsorption and growth. In addition, KD treatment was associated with improvements in several patient-reported outcome measures. In conclusion, this single-case observation provides preliminary clinical evidence supporting the translational potential of ketogenic dietary therapy in cystinosis. These findings strengthen the rationale for prospective clinical studies to evaluate the safety, feasibility, and efficacy of KD in a larger cohort of patients with cystinosis.

Authors

Institutions

Publication Details

Journal
Orphanet Journal of Rare Diseases
Published
2026-11-13
DOI
https://doi.org/10.1186/s13023-026-04706-7
Primary Topic
Biomedical Research and Pathophysiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Ketogenic diet improves renal Fanconi syndrome in nephropathic cystinosis: first human proof-of-principle from an n-of-1 pediatric study

Annet Maria Bosch, Maud M. van Muilekom, Fanny Oliveira Arcolino, Clara van Karnebeek et al.
2 links
Orphanet Journal of Rare Diseases
Biomedical Research and Pathophysiology
article

Ketogenic diet improves renal Fanconi syndrome in nephropathic cystinosis: first human proof-of-principle from an n-of-1 pediatric study

Annet Maria Bosch, Maud M. van Muilekom, Fanny Oliveira Arcolino, Clara van Karnebeek, Elena N. Levtchenko, Francesco Emma, Francesco Bellomo, Arend Bökenkamp, Annelieke Muller, Josephina Koppes, Saskia van der Lee-van Diest
article en

Abstract

Abstract Cystinosis is a rare inherited metabolic disorder caused by pathogenic variants in the CTNS gene and characterized by progressive lysosomal cystine accumulation in virtually all organs and tissues. Clinically, the disease presents with renal Fanconi syndrome (RFS) during the first year of life and, if left untreated, progresses to end-stage kidney disease around the age of 10 years. In addition to renal involvement, cystinosis affects multiple extra-renal organs, including the eyes, thyroid gland, muscles, brain, pancreas, and gonads. Treatment with the cystine-depleting agent cysteamine delays disease progression. In two rodent models of cystinosis (mouse and rat), a ketogenic diet (KD) has recently been shown to markedly improve features of RFS and chronic kidney injury. Inspired by these findings, we initiated KD treatment in a 7-year-old boy with cystinosis and RFS. The diet was administered via a gastrostomy tube for six months. Following an initial adaptation period, the intervention was well tolerated. After three and six months of treatment, we observed substantial improvements in proximal tubular reabsorption and growth. In addition, KD treatment was associated with improvements in several patient-reported outcome measures. In conclusion, this single-case observation provides preliminary clinical evidence supporting the translational potential of ketogenic dietary therapy in cystinosis. These findings strengthen the rationale for prospective clinical studies to evaluate the safety, feasibility, and efficacy of KD in a larger cohort of patients with cystinosis.

Orphanet Journal of Rare Diseases
Amsterdam UMC Location University of Amsterdam (NL), Emma Kinderziekenhuis (NL), Bambino Gesù Children's Hospital (IT), Amsterdam University Medical Centers (NL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Amsterdam (NL)
Good health and well-being
Biomedical Research and Pathophysiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon